SONIRE Therapeutics Begins a Randomized Phase 2 Clinical Study For Patients With Unresectable Pancreatic Cancer

SONIRE Therapeutics (Head Office: Shinjuku-ku, Tokyo; President and CEO: Tohru Satoh; hereinafter referred to as ‘SONIRE’) announced the initiation of a randomized Phase 2 clinical study to evaluate the safety and efficacy of its novel High-Intensity Focused Ultrasound (HIFU) therapy. In this clinical trial, the efficacy of HIFU treatment in combination with second-line chemotherapy will be evaluated in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy. The primary endpoint of the study is overall survival.

SONIRE has been developing its HIFU treatment device as a new therapeutic modality for pancreatic cancer, one of the most intractable malignancies. Fast Track Initiative (FTI) sees strong potential in HIFU as a new treatment paradigm for intractable solid tumors, given its minimally invasive nature, low side effect profile, and absence of radiation exposure. FTI Principal Hiroko Kimura has served as an External BoD member since the company’s Series A round.

To read the original announcement, visit https://www.sonire-therapeutics.com/en/announcement-of-first-patient-enrolled-in-a-randomized-phase-2-study-of-sonires-novel-hifu-therapy-system-for-unresectable-pancreatic-cancer-patients-in-japan/ View details of the study here: https://clinicaltrials.gov/ct2/show/NCT05601323?term=NCT05601323&draw=2&rank=1  

  About SONIRE Therapeutics: SONIRE was established in February 2020 to develop the next-generation High-Intensity Focused Ultrasound (HIFU) system using the technology and clinical know-how has been built by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University over the past years. HIFU therapy is expected as a new cancer treatment because it is non-invasive with no risk of radiation, so patients can receive the treatment repeatedly. SONIRE has developed the HIFU therapy system as a new treatment modality targeting intractable cancers such as pancreatic cancer. Visit our homepage here: https://www.sonire-therapeutics.com/en/   About Fast Track Initiative: Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm, focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to their exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/.  For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com